Federal health regulators announced Wednesday they will assemble an independent advisory committee this July to determine whether specialty compounding pharmacies should regain permission to produce more than half a dozen peptide compounds that have surged in popularity.
These substances are composed of short amino acid chains that serve as protein building blocks and carry out vital functions throughout the human body.
The compounds being reconsidered were part of a group of 14 products that federal regulators prohibited compounding pharmacies from creating in 2023 during the Biden presidency, pointing to concerns about immune reactions, toxic effects, and contamination issues.
Health officials have maintained that insufficient human testing exists for most of these substances, potentially creating health hazards for users.
Even without comprehensive safety and efficacy research, these compounds have become extremely popular among social media wellness personalities, who frequently endorse them online for healing injuries, reducing inflammation, and losing weight.
The fitness world has also embraced these substances recently, boosted partly by the widespread success of peptide-derived GLP-1 medications for weight management like semaglutide and tirzepatide.
This regulatory reconsideration comes after public endorsement from Health Secretary Robert F. Kennedy Jr., who recently stated on the Joe Rogan podcast that he is a “big fan of peptides” and has used them himself with “really good effect.”
During the July 23 session, committee members will evaluate whether manufacturers should produce BPC-157 for ulcerative colitis treatment, KPV for healing wounds and inflammatory conditions, TB-500 for wound repair, and MOTS-c for obesity and osteoporosis management.
The following day’s July 24 meeting will focus on emideltide for treating opioid withdrawal, chronic sleep disorders, and narcolepsy, semax for brain blood flow issues, migraines, and certain chronic pain conditions, and epitalon for sleep problems.
